Hikal Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/h2knnxzmgrwef9c8vt93w0tv.pdf

Key Takeaways


The US FDA OAI Event: Impact, Response and Customer Fallout

Manoj Mehrotra: "There's nothing systemically wrong with Hikal facility or practices. Observations were mostly procedural, and we are confident of resolving them by end of September."

Pharma Segment: Deferral, Recovery and the CDMO Shift

Sameer Hiremath: "I would like to reiterate again that no orders have been canceled, and all contracts are in place and customers reaffirmed their commitment to pick up the product from us within Q2 and Q3."

Crop Protection: Overcapacity and a Waiting Game


Diversification Bets: Animal Health, Personal Care and Specialty Conversion


Margins, CAPEX and the Pinnacle Plan


Guidance & Commitments

CommitmentSpecificsTimeline
Pharma revenue growth12-14% YoY growthFY26
Deferred revenue recovery~₹50 crores recoveredQ2 and Q3 FY26
OAI CAPA completionRemaining corrective actions closed outEnd of Q2 FY26 (September)
CDMO commercial revenuesFirst commercial revenues from CDMO projectsEnd of FY26
Animal Health commercial launchesCommercial quantities begin post-validationFY26 and beyond; 12-14 months after validation completes next quarter
Specialty chem plant conversionValidation and commercial production startNext 6-9 months
CDMO-to-owned mixShift to 70:30 splitNext couple of years
Food & nutraceuticals peak outputReach peak outputNext 18-24 months
CAPEXRs. 200 croresFY26
CAPEX returnsAll CAPEX to start delivering expected returnsFY28-FY29
Crop capacity utilizationSignificant growth in utilization, bringing operating leverageFY27-FY28

Key Metrics

MetricQ1 FY26
Consolidated revenue₹380 cr, vs ₹407 cr in Q1 FY25
EBITDA₹25 cr, margin 6.5% vs 14.3% in Q1 FY25
Cash profit₹16 cr
Free cash flow₹15 cr, positive
Depreciation₹39 cr
Finance costs₹17 cr
CAPEX₹31 cr; full-year guidance ₹200 cr
Debt-to-equity ratio0.54
Pharma revenue₹203 cr, EBIT loss of ₹27 cr; 11.7% YoY degrowth
Crop protection revenue₹178 cr, EBIT ₹17 cr; largely flat YoY
Pharma revenue growth guidance (FY26)12% to 14%
Crop protection revenue growth guidance (FY26)Flattish
Revenue deferment (Pharma)~₹50 cr deferred from Q1 to Q2 and Q3
OAI remediation cost (FY26)₹10 cr to ₹12 cr total; ~₹5 cr expensed in Q1
CAPA completion75% to 80% corrected; balance expected by end of Q2
CDMO / own-product revenue split60:40 currently, moving toward 70:30 in next couple of years
Animal Health portfolio filed from Panoli80% to 90%
Pharma molecules under development8 to 9
Crop protection development pipeline8 projects
Food & nutraceutical peak output timeline18 to 24 months
Key starting materials commercial launchExpected by FY27